IL28B POLYMORPHISM AND KINETICS OF ANTIVIRAL ACTIVITY FOR ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAiVE GENOTYPE-1 CHRONIC HCV PATIENTS

被引：0

作者：

Muir, Andrew J. ^{[1
]}

Lawitz, Eric ^{[2
]}

Rodriguez-Torres, Maribel

Rustgi, Vinod K. ^{[3
]}

Hassanein, Tarek ^{[4
]}

Appleman, James R. ^{[5
]}

Crowley, Constance A. ^{[5
]}

Freddo, James L. ^{[5
]}

McHutchison, John G. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr, DCRI, Durham, NC USA

[2] Alamo Med Res, San Antonio, TX USA

[3] Metropolitan Res, Fairfax, VA USA

[4] SCTI Res Fdn, Ctr Liver, San Clemente, CA USA

[5] Anadys Pharmaceut Inc, San Diego, CA USA

来源：

HEPATOLOGY | 2010年 / 52卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1852

引用

页码：1200A / 1200A

页数：1

共 50 条

[1] SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
Lawitz, Eric
Rodriguez-Torres, Maribel
Rustgi, Vinod K.
Hassanein, Tarek
Rahimy, Mohamad H.
Crowley, Constance A.
Freddo, James L.
Muir, Andrew J.
McHutchison, John G.
HEPATOLOGY, 2010, 52 (04) : 334A - 335A
[2] SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS
Lawitz, E.
Rodriquez-Torres, M.
Rustgi, V. K.
Hassanein, T.
Rahimy, M. H.
Crowley, C. A.
Freddo, J. L.
Muir, A.
McHutchison, J.
JOURNAL OF HEPATOLOGY, 2010, 52 : S467 - S467
[3] VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION
Asselah, T.
Jensen, D. M.
Foster, G. R.
Sulkowski, M. S.
Ouzan, D.
Morano, L.
Buynak, R.
Agarwal, K.
Hassanein, T.
Forton, D.
Cho, M.
Genne, D.
Kaita, K.
Maieron, A.
Preotescu, L.
Sarrazin, C.
Zehnter, E.
Streinu-Cercel, A.
Stern, J. O.
Datsenko, Y.
Drulak, M.
Voss, F.
Quinson, A. -M.
Ferenci, P.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S311 - S311
[4] Virological Response in Treatment-Naive Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction
Asselah, Tarik
Jensen, Donald M.
Foster, Graham
Sulkowski, Mark
Ouzan, Denis
Morano, Luis
Buynak, Robert
Agarwal, Kosh
Hassanein, Tarek
Forton, Daniel
Cho, Mong
Genne, Daniel
Kaita, Kelly
Maieron, Andreas
Preotescu, Liliana
Sarrazin, Christoph
Zehnter, Elmar
Streinu-Cercel, Adrian
Stern, Jerry O.
Datsenko, Yakov
Drulak, Murray
Voss, Florian
Quinson, Anne-Marie
Ferenci, Peter
GASTROENTEROLOGY, 2014, 146 (05) : S975 - S976
[5] The importance of IL28B polymorphism in response to pegylated interferon α and ribavirin in chronic hepatitis caused by HCV genotype 1b
Mach, Tomasz
Ciesla, Andrzej
Sanak, Marek
Glowacki, Mikolaj
Warunek, Wioleta
Owczarek, Danuta
Ciecko-Michalska, Irena
PRZEGLAD GASTROENTEROLOGICZNY, 2012, 7 (01): : 38 - 42
[6] IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONα-2A AND RIBAVIRIN IN PILLAR STUDY
Aerssens, J.
Fanning, G.
Scholliers, A.
Lenz, O.
Peeters, M.
De Smedt, G.
Fried, M.
JOURNAL OF HEPATOLOGY, 2011, 54 : S5 - S6
[7] EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON α-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS
Jacobson, I. M.
Jensen, D. M.
Dieterich, D.
Sarrazin, C.
Foster, G. R.
Yoshida, E. M.
Nelson, M.
Ingiliz, P.
Soriano, V.
Cooper, C.
Stern, J. O.
Quinson, A. -M.
Kukolj, G.
Scherer, J.
Drulak, M.
Gallivan, J. -P.
Schobelock, M.
Ferenci, P.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S457 - S457
[8] Effect of HCV Genotype-1 Subtype on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naive Patients: Pooled Data From Phase III Trials
Jacobson, Ira M.
Jensen, Donald M.
Dieterich, Douglas T.
Sarrazin, Christoph
Foster, Graham
Yoshida, Eric M.
Nelson, Mark
Ingiliz, Patrick
Soriano, Vicente
Cooper, Curtis
Stern, Jerry O.
Quinson, Anne-Marie
Kukolj, George
Scherer, Joseph
Drulak, Murray
Gallivan, John-Paul
Schobelock, Michael
Ferenci, Peter
GASTROENTEROLOGY, 2014, 146 (05) : S976 - S976
[9] FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES
Asselah, T.
Jensen, D. M.
Foster, G. R.
Sulkowski, M. S.
Ouzan, D.
Morano, L.
Buynak, R.
Agarwal, K.
Hassanein, T.
Forton, D.
Negro, F.
Genne, D.
Kaita, K.
Maieron, A.
Preotescu, L.
Sarrazin, C.
Zehnter, E.
Romero-Gomez, M.
Stern, J. O.
Quinson, A. -M.
Drulak, M.
Garcia, M.
Voss, F.
Boecher, W.
Ferenci, P.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S310 - S311
[10] Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naive Patients: Pooled Analysis of Phase III Studies
Asselah, Tarik
Jensen, Donald M.
Foster, Graham
Sulkowski, Mark
Ouzan, Denis
Morano, Luis
Buynak, Robert
Agarwal, Kosh
Hassanein, Tarek
Forton, Daniel
Negro, Francesco
Genne, Daniel
Kaita, Kelly
Maieron, Andreas
Preotescu, Liliana
Sarrazin, Christoph
Zehnter, Elmar
Romero-Gomez, Manuel
Stern, Jerry O.
Quinson, Anne-Marie
Drulak, Murray
Garcia, Miguel
Voss, Florian
Boecher, Wulf
Ferenci, Peter
GASTROENTEROLOGY, 2014, 146 (05) : S977 - S977

← 1 2 3 4 5 →